Blog
Published June 2, 2020
Executive Summary
China’s 2019 National Reimbursement Drug List (NRDL) update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas; although in most disease areas the comparative negotiation rule was employed during the 2019 NRDL, the use of a new competitive negotiation rule employed in the hepatitis C disease area characterized the 2019 NRDL negotiations; under this rule, no base price was set and manufacturers were invited to…
Read Now
Briefs
Trinity explores some of the immediate challenges presented to New Products Planning (also known as Early Commercial Planning or New Product Commercialization) groups.
Publication Access Form…
Read Now
Briefs
While COVID-19 is grinding world economies to a potentially disastrous halt, the pharmaceutical and biotech industry continues to move forward at a slower pace.
How can companies ensure an agile launch despite the uncertainty and ensure launch success during and in a post-COVID-19 world?
Publication Access Form…
Read Now
Briefs
Highlights from Trinity’s Recent Research Focused on Telehealth
Since earlier this year when the COVID-19 virus outbreak began and quickly made its way around the globe, the way in which we operate has changed.
Virtual communication for personal as well as business interactions is on the rise.
Publication Access Form…
Read Now
Briefs
Highlights from Trinity’s Recent Research Focused on European HCP
The COVID-19 pandemic continues to have an unprecedented impact on our lives and is disrupting businesses as it spreads worldwide.
As the EU5 countries comprise some of the most important pharmaceutical markets, and with Italy, Spain and France includes countries which have been impacted significantly from COVID-19, Trinity aimed to understand the impact on HCP engagement with Market Research.
Publication access form…
Read Now
Briefs
Perspectives from 50+ Industry Forecasting Leaders, Highlights from Trinity’s Recent Research Focused on BioPharma Forecasting
In a time of peak uncertainty, forecasters are being called on to answer some of the industry’s toughest questions surrounding the impact of COVID-19.
Trinity is bringing together the latest data on challenges forecasters have been experiencing over the past few weeks. This research activity is a joint project of Trinity’s Forecasting Center of Excellence and its benchmarking division, TGaS Advisors.
Publication Access Form…
Read Now
Briefs
The COVID-19 pandemic continues to have an unprecedented impact on our lives and is disrupting businesses as it spreads worldwide. The social distancing measures that are critically important to address the pandemic present new challenges with patient recruitment for clinical trials, market research, and drug launches.
In this time of uncertainty, Trinity is assessing the impact on market research services including the ability of healthcare providers to participate in research.
In its latest brief, “Impact of COVID-19 on Healthcare Market…
Read Now
Case Studies
Trinity conducted a payer and employer advisory board to understand current perceptions of novel migraine therapies and potential strategies to improve access.
Geographic Scope:
Client Situation
The client wanted to gather the payer and employer perspective on how the migraine landscape is evolving, and pressure test key strategic options as well as messages that they had developed. The employers included: Coca-Cola Company, Metro Nashville Public Schools, St. Louis Community College, and Vibra Healthcare.
Trinity’s Solution
Trinity conducted an unblinded advisory board with a diverse…
Read Now
White Papers
2018 and 2019 were banner years for approvals with over 50 drugs approved by the FDA and the EMA each year. 2020 looks no different. As you prepare for your unique launch in an ever-changing landscape, we understand the challenges you may face: limited resources, lack of prioritization, misalignment, diversity of markets. Based on Trinity’s experience supporting dozens of launches in 2019 alone and through a landmark research study with 30 Chief Commercial Officers (CCOs) who had recently launched a product, we…
Read Now
White Papers
By 2022 Europe is forecast to account for 20% of a global US$1.2 trillion pharmaceutical market. For executives from emerging biopharmaceutical companies planning to develop and commercialize their assets in Europe, the views of biopharmaceutical investors are critical, as investors provide the necessary investments. Additionally, investors who have analyzed numerous biopharmaceutical companies will have valuable experience on what drives commercial success.
In this paper, we aim to understand the views of both investors and biopharmaceutical companies, specifically on the investments…
Read Now
